Literature DB >> 2964490

Suppressor cell activation and enhanced skin allograft survival after tumor promotor but not initiator induced depletion of cutaneous Langerhans cells.

G M Halliday1, K A Odling, J C Ruby, H K Muller.   

Abstract

During chemical carcinogenesis Langerhans cells (LC) are depleted from the epidermis, disrupting the normal immunological functions of the skin. Tumor promotors but not initiators, have been shown to deplete adenosine triphosphatase (ATPase)-positive LC from the skin and therefore the cutaneous immune system may be impaired during tumor promotion but not initiation. The present study shows that the tumor promotor 12-O-tetradecanoylphorbol 13-acetate (TPA) but not the initiator urethane depletes Ia-positive LC from BALB/c murine ear epidermis, and beta-glucuronidase-positive LC from C57BL mouse tail skin. Sensitization with 2,4-dinitrofluorobenzene (DNFB) through urethane-treated skin resulted in a normal contact sensitivity response when the mice were challenged 5 days later. In contrast, tolerance resulted from sensitization through TPA-treated skin as a result of the generation of suppressor cells. In addition, TPA but not urethane-treated C57BL mouse tail skin survived for an extended time when grafted onto histoincompatible BALB/c mice. Therefore, impairment of the normal immunological functions of skin resulted from treatment with the tumor promotor TPA but not the tumor initiator urethane, which suggests that a loss of LC during tumor promotion may impair immunological protection against skin tumors.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2964490     DOI: 10.1111/1523-1747.ep12456077

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  10 in total

1.  Presentation of antigen to suppressor cells by a dimethylbenz (a) anthracene-resistant, Ia-positive, Thy-1-negative, I-J-restricted epidermal cell.

Authors:  G M Halliday; R C Wood; H K Muller
Journal:  Immunology       Date:  1990-01       Impact factor: 7.397

2.  Topical and oral retinoids protect Langerhans' cells and epidermal Thy-1+ dendritic cells from being depleted by ultraviolet radiation.

Authors:  K K Ho; G M Halliday; R S Barnetson
Journal:  Immunology       Date:  1991-11       Impact factor: 7.397

3.  Effects of gliotoxin on Langerhans' cell function: contact hypersensitivity responses and skin graft survival.

Authors:  P C McMinn; G M Halliday; H K Muller
Journal:  Immunology       Date:  1990-09       Impact factor: 7.397

4.  Elevated epidermal ornithine decarboxylase activity suppresses contact hypersensitivity.

Authors:  Martin P Keough; Candace S Hayes; Karen DeFeo; Susan K Gilmour
Journal:  J Invest Dermatol       Date:  2010-09-16       Impact factor: 8.551

5.  Chemical carcinogens and antigens induce immune suppression via Langerhans' cell depletion.

Authors:  G M Woods; M Qu; S J Ragg; H K Muller
Journal:  Immunology       Date:  1996-05       Impact factor: 7.397

6.  Protein kinase C transduces the signal for Langerhans' cell migration from the epidermis.

Authors:  G M Halliday; A D Lucas
Journal:  Immunology       Date:  1993-08       Impact factor: 7.397

7.  Control of Langerhans' cell density by a skin tumour-derived cytokine.

Authors:  G M Halliday; A D Lucas; R S Barnetson
Journal:  Immunology       Date:  1992-09       Impact factor: 7.397

8.  Retinoic acid protects Langerhans' cells from the effects of the tumour promotor 12-O-tetradecanoylphorbol 13-acetate.

Authors:  G M Halliday; J L Dickinson; H K Muller
Journal:  Immunology       Date:  1989-07       Impact factor: 7.397

9.  Langerhans cell migration patterns from sheep skin following topical application of carcinogens.

Authors:  S J Ragg; G W Dandie; G M Woods; P J O'Connell; H K Muller
Journal:  Int J Exp Pathol       Date:  1994-02       Impact factor: 1.925

10.  Spontaneous regression of human melanoma/nonmelanoma skin cancer: association with infiltrating CD4+ T cells.

Authors:  G M Halliday; A Patel; M J Hunt; F J Tefany; R S Barnetson
Journal:  World J Surg       Date:  1995 May-Jun       Impact factor: 3.352

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.